Farnesyl protein transferase inhibitors as potential cancer chemopreventives

Cancer Epidemiology Biomarkers and Prevention

Volumn 6, Issue 4, 1997, Pages 267-282

  Kelloff, Gary J ^a   Lubet, Ronald A ^a   Fay, Judith R ^b   Steele, Vernon E ^a   Boone, Charles W ^a   Crowell, James A ^a   Sigman, Caroline C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG;

CANCER; CARCINOGENESIS; ENZYME INHIBITION; GENE MUTATION; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTICARCINOGENIC AGENTS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CRICETINAE; FARNESYLTRANSTRANSFERASE; HUMANS; MICE; PROTO-ONCOGENE PROTEINS P21(RAS); RATS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFERASES;

EID: 0030989097     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (3)

1. Kelloff, G. J., Fay, J. R., Steele, V. E., Lubet, R. A., Boone, C. W., Crowell, J. A., and Sigman, C. C. Epidermal growth factor receptor tyrosine kinase Inhibitors as potential cancer chemopreventives. Cancer Epidemiol., Biomarkers & Prev., 5: 657-666, 1996.
2. Kelloff, G. J., Boone, C. W., Crowell, J. A., Steele, V. E., Lubet, R., and Sigman, C. C. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol., Biomarkers & Prev., 3: 85-98, 1994.
3. Kelloff, G. J., Boone, C. W., Steele, V. E., Fay, J. R., Lubet, R. A., Crowell, J. A., and Sigman, C. C. Mechanistic considerations in chemopreventive drug development. J. Cell. Biochem. Suppl., 20: 1-24, 1994.